Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients.

Piechnik A, Dmoszynska A, Omiotek M, Mlak R, Kowal M, Stilgenbauer S, Bullinger L, Giannopoulos K. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer. 2013 Sep 15; 133(6):1489-96.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.